Khaled Musallam/LinkedIn
Nov 20, 2025, 16:47
Khaled Musallam Takes on The Role as Chief of Cell/Gene Therapies and Hematology at Burjeel Cancer Institute
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared on LinkedIn:
”Priviliged to be working with my friend Prof.Humaid Al-Shamsi to build on the strong foundations of BCI and lead the expansion of hematology services across the network, including dedicated programs in both classical (benign) and malignant hematology, and advanced cell and gene therapies through innovative clinical trials and strategic international partnerships with industry innovators.”
Stay updated with Hemostasis Today.
-
Dec 15, 2025, 15:58Khaled Musallam Applauds Hatoon Ezzat’s Leadership and Healthcare Advances in Saudi Arabia
-
Dec 15, 2025, 12:46Deborah Ebert Long on Hemophilia Care: Progress, Possibility, and the Power of Listening
-
Dec 15, 2025, 12:34Nathan Connell on Conversion from Eptacog Alfa to Beta
-
Dec 15, 2025, 12:17Danny Hsu on Interdisciplinary Toolkit for Gynecologic Bleeding on Anticoagulation
-
Dec 15, 2025, 12:08Ted Roh: A Historic Milestone for Indonesia’s Health Innovation
-
Dec 15, 2025, 11:28Wolfgang Miesbach Shares Insights from Davide Matino’s Presentation on Marstacimab at ASH25
-
Dec 15, 2025, 11:12Tushar Pandey Awarded for His Enourmous Contribution to Hematology
-
Dec 15, 2025, 11:07DISTRO: Vidya Rajbhoj on AI and Digital Technology to Improve Stroke Rehabilitation
-
Dec 15, 2025, 11:00Ischemic Stroke, AF and Atherosclerotis: Amira Khater on Sufficiency of Anticoagulant Monotherapy